Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focusing on small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in three major investor conferences in April and May 2025.

The company will participate in:

• Jones Trading Virtual CNS Symposium - fireside chat on April 29, 2025 (11:00-11:25am ET)
• Citizens JMP 2025 Life Sciences Conference in New York City - fireside chat on May 8, 2025 (1:30-1:55pm ET)
• Mizuho Neuro & Ophthalmology Summit 2025 in New York City - investor meetings on May 21, 2025

Live and archived webcasts of the Jones Trading and Citizens JMP fireside chats will be accessible through the Investors section of Rapport's website.

BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences.

Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET.

Citizens JMP 2025 Life Sciences Conference (New York City) - fireside chat on Thursday, May 8, 2025, from 1:30-1:55pm ET.

Mizuho Neuro & Ophthalmology Summit 2025 (New York City) - investor meetings on Wednesday, May 21, 2025.

Interested parties may access the live and archived webcasts of the Jones Trading and Citizens JMP fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com

Source: https://www.rapportrx.com/
        

FAQ

What investor conferences will Rapport Therapeutics (RAPP) attend in Spring 2025?

Rapport will attend three conferences: Jones Trading Virtual CNS Symposium (April 29), Citizens JMP Life Sciences Conference (May 8), and Mizuho Neuro & Ophthalmology Summit (May 21, 2025).

How can investors access Rapport Therapeutics (RAPP) conference presentations?

Investors can access live and archived webcasts of the Jones Trading and Citizens JMP fireside chats through Rapport's website at investors.rapportrx.com.

What is the schedule for Rapport Therapeutics' (RAPP) fireside chats in April-May 2025?

Rapport has scheduled fireside chats on April 29 (11:00-11:25am ET) at Jones Trading Symposium and May 8 (1:30-1:55pm ET) at Citizens JMP Conference.

Which in-person investor events will Rapport Therapeutics (RAPP) attend in New York City?

Rapport will attend two in-person events in New York City: the Citizens JMP Life Sciences Conference (May 8) and the Mizuho Neuro & Ophthalmology Summit (May 21).